Antivirals For COVID

Richard Marsden, CEO of Synairgen plc discusses full results from its SGO16 Phase II trial of its inhaled interferon beta formulation (SNG001) for the treatment of severe viral lung infections in COVID-19 patients. The combined analysis of the home and hospital cohorts shows that breathless patients are more than 3 times as likely to recover on SNG001 than placebo. Unique to SNG001 is that it is inhaled therefore targeting response at the site of infection.
Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

#COVID19 #Antiviral #Synairgen

Visit our website

Follow us on our social media channels

Subscribe to our podcast channels

Support us on Patreon

[mattwilliamson]

Let's get this treatment out into home and hospital across the land.

[clikerzbot]

Hey boss if you could make this at large volumes and at a price where we third world countries could afford..then your drug could save us the world and pay you for your work with gratitude. Not like this greedy vaccine manufacturers. Hope your company will be successful on all your trials. We in the philippines are counting on this.

[cliveevrall]

I am curious to know if this treatment would work in the case of Farmer's Lung. My late father suffered from it for many years and it blighted his life.
An occupational hazard in anýone working in agriculture apparently and more widely than one might think.

[matthat]

Sounds very positive, hopefully the results from the active2 / warp speed trials will have enough breathless patients, so confirming the current hypothesis and ensuring phase 3 partisapation.